• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Science . Mapping SARS-CoV-2 antigenic relationships and serological responses

tetano

Editor, Senior Moderator
Science


. 2023 Oct 6;382(6666):eadj0070.
doi: 10.1126/science.adj0070. Epub 2023 Oct 6. Mapping SARS-CoV-2 antigenic relationships and serological responses

Samuel H Wilks[SUP] #[/SUP][SUP] 1 [/SUP], Barbara Mühlemann[SUP] #[/SUP][SUP] 2 3 [/SUP], Xiaoying Shen[SUP] #[/SUP][SUP] 4 5 [/SUP], Sina Türeli[SUP] 1 [/SUP], Eric B LeGresley[SUP] 1 [/SUP], Antonia Netzl[SUP] 1 [/SUP], Miguela A Caniza[SUP] 6 [/SUP], Jesus N Chacaltana-Huarcaya[SUP] 7 [/SUP], Victor M Corman[SUP] 2 3 [/SUP], Xiaoju Daniell[SUP] 4 [/SUP], Michael B Datto[SUP] 8 [/SUP], Fatimah S Dawood[SUP] 9 [/SUP], Thomas N Denny[SUP] 5 [/SUP], Christian Drosten[SUP] 2 3 [/SUP], Ron A M Fouchier[SUP] 10 [/SUP], Patricia J Garcia[SUP] 11 [/SUP], Peter J Halfmann[SUP] 12 [/SUP], Agatha Jassem[SUP] 13 [/SUP], Lara M Jeworowski[SUP] 2 [/SUP], Terry C Jones[SUP] 1 2 3 [/SUP], Yoshihiro Kawaoka[SUP] 12 14 15 16 [/SUP], Florian Krammer[SUP] 17 18 [/SUP], Charlene McDanal[SUP] 4 [/SUP], Rolando Pajon[SUP] 19 [/SUP], Viviana Simon[SUP] 17 18 20 21 [/SUP], Melissa S Stockwell[SUP] 22 [/SUP], Haili Tang[SUP] 4 [/SUP], Harm van Bakel[SUP] 23 [/SUP], Vic Veguilla[SUP] 9 [/SUP], Richard Webby[SUP] 24 [/SUP], David C Montefiori[SUP] 4 5 [/SUP], Derek J Smith[SUP] 1 [/SUP]



Affiliations
Abstract

During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, multiple variants escaping preexisting immunity emerged, causing reinfections of previously exposed individuals. Here, we used antigenic cartography to analyze patterns of cross-reactivity among 21 variants and 15 groups of human sera obtained after primary infection with 10 different variants or after messenger RNA (mRNA)-1273 or mRNA-1273.351 vaccination. We found antigenic differences among pre-Omicron variants caused by substitutions at spike-protein positions 417, 452, 484, and 501. Quantifying changes in response breadth over time and with additional vaccine doses, our results show the largest increase between 4 weeks and >3 months after a second dose. We found changes in immunodominance of different spike regions, depending on the variant an individual was first exposed to, with implications for variant risk assessment and vaccine-strain selection.


 
Back
Top Bottom